拉科酰胺
Lacosamide.
作者信息
Perucca Emilio, Yasothan Uma, Clincke Gilbert, Kirkpatrick Peter
机构信息
Department of Internal Medicine and Therapeutics and Institute of Neurology, IRCCS C Mondino Foundation, University of Pavia, Italy.
出版信息
Nat Rev Drug Discov. 2008 Dec;7(12):973-4. doi: 10.1038/nrd2764.
DOI:10.1038/nrd2764
PMID:19043448
Abstract
In August 2008, lacosamide (Vimpat; UCB), was granted market authorization by the European Commission as an adjunctive therapy for partial-onset seizures with or without secondary generalization in patients with epilepsy. It was approved by the FDA as an adjunctive therapy for partial-onset seizures in October 2008.
摘要
2008年8月，拉科酰胺（万适宁；优时比公司）获欧盟委员会批准，作为辅助疗法用于治疗癫痫患者伴有或不伴有继发性全面发作的部分性发作。2008年10月，它获美国食品药品监督管理局批准作为辅助疗法用于治疗部分性发作。
Zotero 插件